1. Primary Biliary Cholangitis: Promising Emerging Innovative Therapies and Their Impact on GLOBE Scores
- Author
-
Sohal A and Kowdley KV
- Subjects
pbc ,globe scores ,treatments ,therapeutic options ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Aalam Sohal,1 Kris V Kowdley1,2 1Department of Hepatology, Liver Institute Northwest, Seattle, WA, USA; 2Department of Gastroenterology and Hepatology, Elson Floyd College of Medicine, Spokane, WA, USACorrespondence: Kris V Kowdley, Liver Institute Northwest, 3216 NE 45th Pl Suite 212, Seattle, WA, 98105, USA, Email kkowdley@liverinstitutenw.orgAbstract: Primary biliary cholangitis (PBC), previously referred to as primary biliary cirrhosis, is an autoimmune disorder leading to the destruction of intra-hepatic bile ducts. If untreated, progressive bile duct damage and cholestasis can lead to ductopenia and result in cirrhosis. Ursodiol, the first drug approved for PBC, has changed the natural history of this disease and improved patient outcomes. Subsequently, several new prediction models incorporating a response to ursodiol were developed. These include the GLOBE score, which was shown to predict long-term outcomes in patients with PBC. In 2016, obeticholic acid (OCA) became the second drug to be approved by the FDA, predominantly based on improvement in alkaline phosphatase (ALP) levels. This trial has subsequently influenced the design of clinical trials. Several drugs are currently being evaluated as therapeutic options for PBC, with improvement in ALP being a main endpoint. In this review, we will discuss the impact of new therapies on GLOBE scores in patients with PBC.Keywords: PBC, GLOBE scores, treatments, therapeutic options
- Published
- 2023